Many of these new genes are tumor suppressors and oncogenes (including ENO1, PDE4B, HRAS, MUCDHL, FGFR3, CBFA2T3, RNH1, IGF2AS, and CD151), the loss or activation of which may now explain some of the clinical observations of Wilms' tumor patients. This evidence concerns the gene CD151 and Wilms tumor.